This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human E-Cadherin / Cadherin-1 Protein, Fc Tag
catalog :
ECD-H5250
quantity :
100 ug, 1 mg
price :
260 USD, 1600 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
ECD-H5250
product name :
Human E-Cadherin / Cadherin-1 Protein, Fc Tag
quantity :
100 ug, 1 mg
price :
260 USD, 1600 USD
quantity & price :
$260/100ug,$1600/1mg (250ug × 4)
target :
E-Cadherin
host species :
Human
By Tag :
Fc Tag
Research :
For Research Use Only
Source :
Human E-Cadherin, Fc Tag (ECD-H5250) is expressed from human 293 cells (HEK293). It contains AA Gln 23 - Pro 621 (Accession # AAI41839).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human E-Cadherin, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. Cadherin-1 (CDH1) is also known as epithelial cadherin (E-cadherin), CD_antigen (CD324), Uvomorulin (UVO) ECAD and CDHE, CDH1 / CD324 contains 5 cadherin domains. CDH1 / CD324 / ECAD is expressed in non-neural epithelial tissues. CDH1 / E-CAD is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells and has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7. E-Cad promotes non-amyloidogenic degradation of Abeta precursors and has a strong inhibitory effect on APP C99 and C83 production. Defects in CDH1 / CD324 / ECAD are the cause of hereditary diffuse gastric cancer (HDGC).
References :
(1) Agiostratidou G., et al., 2006, J. Neurochem. 96:1182-1188.
(2) Meng Y.G., et al., 2007, Cell Res. 17:869-880.
(3) Yoon K.-A., et al., 1999, J. Hum. Genet. 44:177-180.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments